Analysis of oncology research from 2001 to 2010: A scientometric perspective

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1441-1452

  Shao, Hongfang ^a   Yu, Qi ^a   Bo, Xiaoming ^a   Duan, Zhiguang ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Co citation analysis; Knowledge domain visualisation; Oncology research fronts; Social network analysis

Indexed keywords

BEVACIZUMAB; BREAST CANCER VACCINE; CANCER VACCINE; CERVICAL CANCER VACCINE; CILENGITIDE; ENDOSTATIN; GASTRIC TUMOR CELL VACCINE; GEFITINIB; LUNG TUMOR CELL VACCINE; MELANOCYTE PROTEIN PMEL 17; MELANOMA CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; VACCINE; VASCULOTROPIN ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER INCIDENCE; CANCER RESEARCH; CHINA; CITATION ANALYSIS; GENE EXPRESSION; HUMAN; INFORMATION RETRIEVAL; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCIENCE; SCIENTOMETRICS; SOCIAL NETWORK; UNITED STATES;

DEVELOPING COUNTRIES; HUMANS; INTERNET; MEDICAL ONCOLOGY; NEOPLASMS; PUBLICATIONS; RESEARCH; RESEARCH PERSONNEL;

EID: 84874706831     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2239     Document Type: Review

References (56)

1. Borner K, Chen CM and Boyack KW: Visualizing knowledge domains. Annu Rev Inf Sci Technol 37: 179-255, 2003.
2. Chen Y and Liu ZY: The rise of mapping knowledge domain. Studies in Science of Science 23: 149-154, 2005.
3. Jankovic MP, Kaufmann M and Kindler CH: Active research fields in anesthesia: a document co-citation analysis of the anes-thetic literature. Anesth Analg 5: 1524-1533, 2008.
4. Jarneving B: A comparison of two bibliometric methods for mapping of the research front. Scientometrics 2: 245-263, 2005.
5. Lee MR and Chen TT: Revealing research themes and trends in knowledge management: from 1995 to 2010. Knowledge-Based System 28: 47-58, 2012.
6. Zhao R and Wang J: Visualizing the research on pervasive and ubiquitous computing. Scientometrics 86: 593-612, 2011.
7. Chen CM, McCain K, White H and Lin X: Mapping Scientometrics (1981-2001). Proc 65th Asist Annual Meeting 39: 25-34, 2002.
8. An XY and Wu QQ: Co-word analysis of the trends in stem cell field based on subject heading weighting. Scientometrics 88: 133-144, 2011.
9. Chen CM: CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol 57: 359-377, 2006.
10. Chen C, Ibekwe-San Juan F and Hou J: The structure and dynamics of cocitation clusters: a multiple-perspective cocitation analysis. J Am Soc Inf Sci Technol 61: 1386-1409, 2010.
11. Chen CM: Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA 101: 5303-5310, 2004.
12. Chen CM, Cribbin T, Macredie R and Morar S: Visualizing and tracking the growth of competing paradigms: two case studies. J Am Soc Inf Sci Technol 53: 678-689, 2002.
13. Chen C, Hu Z, Liu S and Tseng H: Emerging trends in regen¬erative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther 12: 593-608, 2012.
14. Small H: Co-citation in the scientific literature: a new measure of the relationship between two documents. J Am Soc Info Sci 24: 265-269, 1973.
15. Liu Z, Chen Y and Chen H: Mapping Knowledge Domains Methods and Application. 1st edition. People Publishing House, Peking, pp34-81, 2008.
16. Liu J: An introduction to Social Network Analysis. 1st edition. Social Science Academic Press (China), Beijing, pp4-25, 2004.
17. Katz JS and Martin BR: What is research collaboration? Res Policy 26: 1-18, 1997.
18. Gossart C and Ozman M: Co-authorship networks in social sciences: the case of Turkey. Scientometrics 78: 323-345, 2009.
19. Lu HY and Feng YQ: A measure of authors' centrality in co-authorship networks based on the distribution of collaborative relationships. Scientometrics 81: 499-511, 2009.
20. Yu Q, Shao H and Duan Z: Research groups of oncology co-authorship network in China. Scientometrics 89: 553-567, 2011.
21. Morel CM, Serruya SJ, Penna GO and Guimarães R: Co-authorship network analysis: a powerful tool for strategic planning of research, development and capacity building programs on neglected diseases. PLoS Negl Trop Dis 3: 8, 2009.
22. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopolous N, Peltomäki P, de la Chapelle A, Hamilton SR, Kinzler KW and Vogelstein B: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9: 48-55, 1995.
23. Issa JP, Baylin SB and Herman JG: DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11: S7-S11, 1997.
24. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
25. Sun C and Wang H: The role of SNAIL gene in gynecologic cacinoma metastasis mechanism. J Int Obstet Gynecol 4: 260-263, 2010.
26. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
27. Sionov RV and Haupt Y: The cellular response to p53: the decision between life and death. Oncogene 45: 6145-6157, 1999.
28. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu XB, Soron G, Cooper B, Brayton C, Park SH, Thompson T, et al: p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53, 2002.
29. Bond GL, Hu WW, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G and Levine AJ: A single nucleo¬tide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004.
30. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352, 1998.
31. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al: Bevacizumab plus irinotecan, fluoro¬uracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
32. Guo QS and Liu YX: Lung cancer target to treatment medicine progress. World Clin Drugs 5: 282-285, 2005.
33. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon T, Naoki K, Sasaki H, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
34. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129 2139, 2004.
35. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
36. Shi W and Li JS: Clinical significance of the expression of ADAM9 in colon carcer. J Southeast University (Medical Science Edition) 4: 274-278, 2009.
37. Kerr JF, Wyllie AH and Currie AR: Apoptosis-basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
38. Liu LJ, Peng JX, Hong HZ, Ye W and Qiao YY: Mitochondrial changes and role in apoptosis. Chin J Cell Biol 27: 117-120, 2005.
39. Green DR and Kroemer G: The pathophysiology of mitochon¬drial cell death. Science 305: 626-629, 2004.
40. Deng C and Shao ZW: Apoptosis of osteosarcoma cells induced by a combination of TRAIL, adriamycin and IFN-?. Cancer Res Prev Treat 1: 1-4, 2010.
41. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al: Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
42. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Masters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
43. Cao ZA, Daniel D and Hanahan D: Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2: 11, 2002.
44. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
45. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J and Sy MS: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263: 518-520, 1994.
46. He TC, Chan TA,Vogelstein B and Kinzler KW: PPAR delta is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell 99: 335-345, 1999.
47. Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell 130: 223-233, 2007.
48. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
49. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
50. Blann AD, Lip GY, Islim IF and Beevers DG: Evidence of platelet activation in hypertension. J Hum Hypertens 11: 607-609, 1997.
51. Chou JJ, Li HL, Salvesen GS, Yuan JY and Wagner G: Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96: 615-624, 1999.
52. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 144: 646-674, 2000.
53. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
54. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
55. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3 Sigma is required to prevent mitotic catas¬trophe after DNA damage. Nature 401: 616-620, 1999.
56. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Sambrook J, et al: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94: 205-215, 2002.